Press Releases
Our latest happenings and recent highlights.
For media inquiries, please contact: Drew.Hewitt@OmniaBio.com
Featured
TORONTO, CANADA & DUBLIN IRELAND — June 15th, 2026 — CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited (“Avectas”) to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The evaluation will explore how Avectas' platform could complement CCRM's growing global network and...
Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026...
TORONTO, CANADA & DUBLIN IRELAND — June 15th, 2026 — CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited (“Avectas”) to evaluate its automated, integrated and scalable cell therapy manufacturing...
HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License...
TORONTO, ONTARIO & BOSTON, MA – October 1st, 2025 – OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence,...
From: Innovation, Science and Economic Development CanadaOmniaBio’s expanded facility in Hamilton seeks to drive a 5X increase in manufacturing efficiency while reducing production and supply costs by up to 50%, facilitating patient access to life-saving...
November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf,...